Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-γ2 phosphorylation and cyclooxygenase-1 activity

Atherosclerosis

Volumn 194, Issue 1, 2007, Pages 144-152

  Jin, Yong Ri ^a   Han, Xiang Hua ^a   Zhang, Yong He ^b   Lee, Jung Jin ^a   Lim, Yong ^a   Chung, Jin Ho ^c   Yun, Yeo Pyo ^a  

^a Chungbuk National University   (South Korea)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c Seoul National University   (South Korea)

Author keywords

Cyclooxygenase 1; Hesperetin; Phospholipase C; Platelet aggregation

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ARACHIDONIC ACID; BIOFLAVONOID; COLLAGEN; CYCLOOXYGENASE 1; HESPERETIN; PHOSPHOLIPASE C GAMMA2; PROSTAGLANDIN D2; SEROTONIN; THROMBOXANE A2; THROMBOXANE SYNTHASE;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CALCIUM MOBILIZATION; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GRAPEFRUIT; IN VITRO STUDY; NONHUMAN; ORANGE (FRUIT); PRIORITY JOURNAL; RABBIT; SEROTONIN RELEASE; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

ANIMALS; ARACHIDONIC ACID; BLOOD PLATELETS; CALCIUM; COLLAGEN; CYCLOOXYGENASE 1; FLAVONOIDS; HESPERIDIN; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDIN D2; RABBITS; SEROTONIN; THROMBOXANE-A SYNTHASE;

EID: 34648837869     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.10.011     Document Type: Article

References (40)

1. Lange R.A., and Hillis L.D. Antiplatelet therapy for ischemic heart disease. N Engl J Med 350 (2004) 277-280
2. Corti R., Fuster V., and Badimon J.J. Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol 41 (2003) 7S-14S
3. Jackson S.P., Nesbitt W.S., and Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 1 (2003) 1602-1612
4. Corti R., Farkouh M.E., and Badimon J.J. The vulnerable plaque and acute coronary syndromes. Am J Med 113 (2002) 668-680
5. Cowan D.H., Robertson A.L., Shook P., and Giroski P. Platelet adherence to collagen: role of plasma, ADP, and divalent cations. Br J Haematol 47 (1981) 257-267
6. Cowan D.H. Platelet adherence to collagen: role of prostaglandin-thromboxane synthesis. Br J Haematol 49 (1981) 425-434
7. Sixma J.J., van Zanten G.H., Huizinga E.G., et al. Platelet adhesion to collagen: an update. Thromb Haemost 78 (1997) 434-438
8. Nieswandt B., and Watson S.P. Platelet-collagen interaction: is GPVI the central receptor?. Blood 102 (2003) 449-461
9. Gibbins J.M. Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 117 (2004) 3415-3425
10. Woulfe D.S. Platelet G protein-coupled receptors in hemostasis and thrombosis. J Thromb Haemost (2005)
11. Awtry E.H., and Loscalzo J. Aspirin. Circulation 101 (2000) 1206-1218
12. Stangl V., Lorenz M., Ludwig A., et al. The flavonoid phloretin suppresses stimulated expression of endothelial adhesion molecules and reduces activation of human platelets. J Nutr 135 (2005) 172-178
13. Hubbard G.P., Wolffram S., Lovegrove J.A., and Gibbins J.M. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost 2 (2004) 2138-2145
14. Cheng J., Kondo K., Suzuki Y., et al. Inhibitory effects of total flavones of Hippophae Rhamnoides L on thrombosis in mouse femoral artery and in vitro platelet aggregation. Life Sci 72 (2003) 2263-2271
15. McGregor L., Bellangeon M., Chignier E., et al. Effect of a micronized purified flavonoid fraction on in vivo platelet functions in the rat. Thromb Res 94 (1999) 235-240
16. Garg A., Garg S., Zaneveld L.J., and Singla A.K. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother Res 15 (2001) 655-669
17. Galati E.M., Trovato A., Kirjavainen S., et al. Biological effects of hesperidin, a citrus flavonoid. (Note III). Antihypertensive and diuretic activity in rat. Farmaco 51 (1996) 219-221
18. Shin Y.W., Bok S.H., Jeong T.S., et al. Hypocholesterolemic effect of naringin associated with hepatic cholesterol regulating enzyme changes in rats. Int J Vitam Nutr Res 69 (1999) 341-347
19. Bok S.H., Lee S.H., Park Y.B., et al. Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl-CoA reductase and acyl CoA: cholesterol transferase are lower in rats fed citrus peel extract or a mixture of citrus bioflavonoids. J Nutr 129 (1999) 1182-1185
20. Wilcox L.J., Borradaile N.M., de Dreu L.E., and Huff M.W. Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. J Lipid Res 42 (2001) 725-734
21. Wilcox L.J., Borradaile N.M., and Huff M.W. Antiatherogenic properties of naringenin, a citrus flavonoid. Cardiovasc Drug Rev 17 (1999) 160-178
22. Born G.V., and Cross M.J. The aggregation of blood platelets. J Physiol 168 (1963) 178-195
23. Orallo F., Alvarez E., Basaran H., and Lugnier C. Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin. Naunyn-Schmiedeberg's Arch Pharmacol 370 (2004) 452-463
24. Kim J.Y., Jung K.J., Choi J.S., and Chung H.Y. Hesperetin: a potent antioxidant against peroxynitrite. Free Radic Res 38 (2004) 761-769
25. Proteggente A.R., Basu-Modak S., Kuhnle G., et al. Hesperetin glucuronide, a photoprotective agent arising from flavonoid metabolism in human skin fibroblasts. Photochem Photobiol 78 (2003) 256-261
26. 2+ mobilization. J Pharmacol Exp Ther 312 (2005) 214-219
27. Kim J.H., Jin Y.R., Park B.S., et al. Luteolin prevents PDGF-BB-induced proliferation of vascular smooth muscle cells by inhibition of PDGF beta-receptor phosphorylation. Biochem Pharmacol 69 (2005) 1715-1721
28. Holmsen H., and Dangelmarier C.A. Measurement of sesretion of serotonin. Meth Enzymol 169 (1989) 205-210
29. Kang W.S., Lim I.H., Yuk D.Y., et al. Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate. Thromb Res 96 (1999) 229-237
30. Tzeng S.H., Ko W.C., Ko F.N., and Teng C.M. Inhibition of platelet aggregation by some flavonoids. Thromb Res 64 (1991) 91-100
31. 2 receptor interaction. J Pharmacol Exp Ther 228 (1984) 240-244
32. Coleman R.A., Smith W.L., and Narumiya S. International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46 (1994) 205-229
33. Mower R.L., Landolfi R., and Steiner M. Inhibition in vitro of platelet aggregation and arachidonic acid metabolism by flavone. Biochem Pharmacol 33 (1984) 357-363
34. Landolfi R., Mower R.L., and Steiner M. Modification of platelet function and arachidonic acid metabolism by bioflavonoids. Structure-activity relations. Biochem Pharmacol 33 (1984) 1525-1530
35. 2 receptor. J Thromb Haemost 3 (2005) 369-376
36. Farndale R.W., Sixma J.J., Barnes M.J., and De Groot P.G. The role of collagen in thrombosis and hemostasis. J Thromb Haemost 2 (2004) 561-573
37. Molino M., Bainton D.F., Hoxie J.A., Coughlin S.R., and Brass L.F. Thrombin receptors on human platelets. Initial localization and subsequent redistribution during platelet activation. J Biol Chem 272 (1997) 6011-6017
38. 2, in platelet activation in response to low concentrations of collagen. Thromb Haemost 85 (2001) 882-889
39. Nielsen I.L., Chee W.S., Poulsen L., et al. Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. J Nutr 136 (2006) 404-408
40. Manach C., Morand C., Gil-Izquierdo A., Bouteloup-Demange C., and Remesy C. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur J Clin Nutr 57 (2003) 235-242